

- CD3 (T3, Leu-4), 372e-3t
 CD4 (T4, Leu-3), 372e-3t
 CD4 surface antigen, 1216, 1218f
 CD4+ T cells
 in adaptive immunity, 372e-9f, 372e-22
 functions of, 372e-17
 helper, 372e-14f, 1673
 in HIV infection
 dysfunction and depletion, 1227–1228, 1231, 1236–1237
 early effects, 1228, 1229f
 HIV-specific, 1244
 latently infected, resting, 1230, 1230f
 for monitoring immunologic competence, 1247–1248, 1248f
 viral invasion, 1216–1217, 1217f, 1229–1230
 in immunity to abscesses, 849
 in *M. tuberculosis* infection, 1107
 in nontuberculous mycobacterial infections, 1129
 in response to viral infections, 214e-8
 in rheumatoid arthritis, 2141, 2142f
 in *T. gondii* infection, 1401
 in transplant rejection, 1827, 1828f
 CD4+ T lymphocytopenia, idiopathic, 1272
 CD7 (3A1, Leu-9), 372e-3t
 CD8 (T8, Leu-2), 372e-3t
 CD8+ cytolytic T lymphocytes (CTLs), in HIV infection, 1229–1230, 1237, 1244
 CD8+ T cells
 in adaptive immunity, 372e-9f
 in COPD, 1701
 in HIV infection, 1237, 1244–1245
 in *L. monocytogenes* infection, 982
 in *M. tuberculosis* infection, 1107
 in response to viral infections, 214e-8
 in *T. gondii* infection, 1401
 in transplant rejection, 1827, 1828f
 CD14 (LPS-receptor)
 in immune response, 372e-2, 372e-3t
 in phagocytosis, 145e-5, 145e-6f
 CD16 (FcyRIIIa), 372e-3t, 372e-6
 CD18 gene mutations, 419
 CD19 (B4), 372e-3t
 CD20 (B1), 372e-3t
 CD21 (B2, C2, EBV-R, C3dR), 372e-3t
 CD22 (BL-CAM), 372e-3t
 CD23 (FceRII), 372e-3t, 372e-8
 CD25, as tumor marker, 473t
 CD28, 372e-3t
 CD30, as tumor marker, 473t
 CD32 (FcyRII), 372e-3t
 CD34 antibodies, 139e-1
 CD40, 372e-3t
 CD40 deficiency, 418, 2110
 CD40 ligand, 276, 742, 2110
 CD40 surface antigen, 276, 742
 CD45 (LCA, T200, B220), 372e-3t
 CD45RA, 372e-3t
 CD45RB, 372e-3t
 CD45RC, 372e-3t
 CD45RO, 372e-3t
 CD56, 372e-6
 CD64 (FcyRI), 372e-3t
 CD80 (B7-1, BB1), 372e-3t
 CD86 (B7-2, B70), 372e-3t
 CD89 (FCaR), 372e-3t
 CD95 (APO-1, Fas), 372e-3t
 CD152 (CTLA-4), 372e-3t
 CD154 (CD40L), 372e-3t
 CD279 (PD-1), 372e-3t
 CDC. *See* Centers for Disease Control and Prevention (CDC)
 CDC73 gene mutations, 2340
 CDCA (chenodeoxycholic acid), 2076
 CD (cluster of differentiation) classification, human leukocyte surface antigens, 372e-1, 372e-3–4t
 CDH1 gene mutations, 101e-6t, 534
 CDK4 gene mutations, 101e-2t, 494
 CDKN2A gene mutations, 494, 554
 CDNK1B gene mutations, 2336t, 2342
 CDX-2, in carcinoma of unknown primary, 120e-2, 120e-2t
 CEA. *See* Carcinoembryonic antigen (CEA)
 CEAP classification, chronic venous insufficiency, 1651, 1652t
 CEBPA gene mutations, 679, 680, 680t
 Cecitis. *See* Enterocolitis, neutropenic
 Cefaclor, 363, 941
 Cefadroxil, 939, 941
 Cefamandole, 941
 Cefazolin
 for cellulitis, 228, 832t
 indications for, 940t, 941, 945t
 for infective endocarditis, 822t, 826t
 for intraabdominal infections, 767t
 prophylactic, 945t
 resistance to, 940t
 for staphylococcal infections, 962t
 Cefdinir, 229t, 941
 Cefepime
 adverse effects of, 942
 for *Citrobacter* infections, 1035
 for community-acquired pneumonia, 808t
 for *Enterobacter* infections, 1034
 for febrile neutropenia, 491
 for gram-negative bacterial infection, 1026
 for health care–associated pneumonia, 767t, 812t
 indications for, 940t, 941
 for intraabdominal infections, 767t
 for meningitis, 887t, 889, 889t
 for osteomyelitis, 840t
 for *P. aeruginosa* infections, 808t, 1045t
 resistance to, 933, 940t
 for sepsis/septic shock, 767t, 780t, 1757t
 Cefixime, 937t, 941, 1009t
 Cefoperazone, 941
 Cefotaxime
 for community-acquired pneumonia, 767t, 808t
 for epiglottitis, 235, 1011
 for gonococcal infections, 1009t
 indications for, 941
 for infective endocarditis, 821, 823
 for intraabdominal infections, 767t
 for leptospirosis, 1145t
 for Lyme disease, 1153, 1153f
 for meningitis, 887t, 889, 889t, 952, 1011
 for meningococcal infections, 1000
 for nongonococcal bacterial arthritis, 835
 for peritonitis, 288, 847, 2066
 for pneumococcal infections, 952
 resistance to, 933
 for sepsis/septic shock, 1757t
 Cefotetan
 for anaerobic bacterial infections, 1101
 indications for, 940t, 941
 for pelvic inflammatory disease, 878t, 879
 prophylactic, 945t
 resistance to, 940t, 1026, 1101
 Cefoxitin
 for anaerobic bacterial infections, 1101
 for bite-wound infections, 167e-2, 167e-3t
 for gas gangrene, 832t, 991t
 for gonococcal infections, 1009t
 indications for, 940t, 941
 for intraabdominal infections, 767t
 for nontuberculous mycobacterial infections, 205e-8
 for pelvic inflammatory disease, 878, 878t, 879
 for peritonitis, 848
 prophylactic, 945t
 resistance to, 940t, 1026, 1101
 for skin and soft tissue infections, 832
 Cefpirome, 941
 Cefpodoxime, 808t, 937t, 941
 Cefprozil, 941
 Ceftaroline
 action of, 961
 indications for, 940t, 941
 for infective endocarditis, 823
 for MRSA infections, 933, 961, 962t
 resistance to, 940t
 Cefazidime
 for febrile neutropenia, 103e-23, 491, 1045t
 for glanders, 1045t
 for health care–associated pneumonia, 767t, 812t
 indications for, 940t, 941
 for intraabdominal infections, 767t
 for melioidosis, 1045t
 for meningitis, 887t
 for nongonococcal bacterial arthritis, 835
 for osteomyelitis, 840t
 for otitis externa, 229
 for *P. aeruginosa* infections, 1045t
 resistance to, 940t
 Ceftriaxone, 1009t, 1091t
 Ceftriaxone
 for actinomycosis, 1091t
 for *Bartonella* endocarditis, 1081t
 for chancroid, 880t, 1013
 for community-acquired pneumonia, 767t, 808t
 for deep neck infections, 235
 for Donovanosis, 198e-2
 drug interactions of, 939t
 empirical uses of, 767t, 780t
 for enteric fever, 1052t
 for enterococcal infections, 975t, 976
 for epididymitis, 872
 for epidural abscess, 767t, 780t
 for epiglottitis, 235, 1011
 for gonococcal infections, 835, 872, 1008, 1009t
 for health care–associated pneumonia, 812t
 indications for, 940t
 for infective endocarditis, 767t, 780t
 Bartonella, 823t
 enterococcal, 821
 HACEK, 183e-1, 183e-2t, 822t
 streptococcal, 822t, 823
 for intraabdominal infections, 767t
 for intracranial infections, 780t
 for leptospirosis, 1145t
 for Lyme disease, 836, 1153, 1153f
 for meningitis, 767t, 780t, 887t, 889, 889t, 952, 1011
 for meningococcal infections, 1000
 for meningococcal prophylaxis, 1003
 for *Neisseria meningitidis* infections, 1087
 for nongonococcal bacterial arthritis, 835
 for nontyphoidal *Salmonella* infections, 1054t
 for osteomyelitis, 840t, 841t
 for otitis media, 229t
 for pelvic inflammatory disease, 878t
 for peritonitis, 847, 848
 for pneumococcal infections, 952
 for postsplenectomy sepsis, 780t
 in pregnancy and lactation, 937t
 prophylactic, 826t, 889
 for purpura fulminans, 780t
 for relapsing fever, 1148, 1148f
 resistance to, 872f, 933, 940t
 for sepsis/septic shock, 1757t
 for *Shigella* infections, 1058t
 for syphilis, 1139
 for Whipple's disease, 1093–1094
 Cefuroxime
 for bite-wound infections, 167e-2
 for community-acquired pneumonia, 808t
 for epiglottitis, 235
 indications for, 941
 for intraabdominal infections, 767t
 for Lyme disease, 1153, 1153f
 for otitis media, 229t
 in pregnancy and lactation, 937t
 Celecoxib
 adverse effects of, 92
 drug interactions of, 43
 genetic variations in response to, 39t
 for gout, 2234
 for osteoarthritis, 2232
 for pain, 91–92, 91t
 for polyposis syndromes, 539
 Celiac disease (gluten-induced enteropathy), 1940
 clinical features of, 1940
 ataxia, 2626
 diarrhea, 269, 1940, 1942